Abstract
Acute lung injury (ALI) is a common, highly lethal acquired disorder that affects over one hundred thousand people each year and for which there are no specific therapies. Extensive investigations in experimental models and humans with ALI have identified several maladaptive host responses and dysregulated protein systems that offer therapeutic opportunities for genetic intervention. Several lines of evidence suggest that gene transfer can be used to deliver protective proteins that improve alveolar epithelial and / or endothelial cell function or immunomodulators that augment lung defense mechanisms and speed clearance of infection. In many instances, gene transfer is the only avenue for producing localized expression of these pharmaceuticals. This article reviews recent translational, animal-based studies that tested the use of gene and cell based therapies to ameliorate or prevent ALI. The lack of effective therapies for ALI and the approachability of the lung for local gene transfer suggest that ALI is a unique example of an acute disease process that is suitable for gene therapy.
Keywords: lung, acute respiratory distress syndrome, acute lung Injury, gene therapy, pulmonary edema
Current Gene Therapy
Title: Potential Genetic Therapies for Acute Lung Injury
Volume: 4 Issue: 4
Author(s): Gokhan M. Mutlu, Alexander T. Ahkmedov, Hazel Lum and Phillip Factor
Affiliation:
Keywords: lung, acute respiratory distress syndrome, acute lung Injury, gene therapy, pulmonary edema
Abstract: Acute lung injury (ALI) is a common, highly lethal acquired disorder that affects over one hundred thousand people each year and for which there are no specific therapies. Extensive investigations in experimental models and humans with ALI have identified several maladaptive host responses and dysregulated protein systems that offer therapeutic opportunities for genetic intervention. Several lines of evidence suggest that gene transfer can be used to deliver protective proteins that improve alveolar epithelial and / or endothelial cell function or immunomodulators that augment lung defense mechanisms and speed clearance of infection. In many instances, gene transfer is the only avenue for producing localized expression of these pharmaceuticals. This article reviews recent translational, animal-based studies that tested the use of gene and cell based therapies to ameliorate or prevent ALI. The lack of effective therapies for ALI and the approachability of the lung for local gene transfer suggest that ALI is a unique example of an acute disease process that is suitable for gene therapy.
Export Options
About this article
Cite this article as:
Mutlu M. Gokhan, Ahkmedov T. Alexander, Lum Hazel and Factor Phillip, Potential Genetic Therapies for Acute Lung Injury, Current Gene Therapy 2004; 4 (4) . https://dx.doi.org/10.2174/1566523043346057
DOI https://dx.doi.org/10.2174/1566523043346057 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Peroxisome Proliferator-Activated Receptor (PPAR)β /δ: A New Potential Therapeutic Target for the Treatment of Metabolic Syndrome
Current Molecular Pharmacology Flavonoids in Neurodegeneration: Limitations and Strategies to Cross CNS Barriers
Current Medicinal Chemistry Erythropoietin: New Approaches to Improved Molecular Designs and Therapeutic Alternatives
Current Pharmaceutical Design Propitious Profile of Peppery Piperine
Current Molecular Pharmacology Nuclear Factor Kappa B is a Promising Therapeutic Target in Inflammatory Lung Disease
Current Drug Targets Organ- and Cell-Type Specific Delivery of Kinase Inhibitors: A Novel Approach in the Development of Targeted Drugs
Current Molecular Pharmacology Neuroprotection by the α2-Adrenoceptor Agonist, Dexmedetomidine, in Experimental Stroke Models
Vascular Disease Prevention (Discontinued) Neuritin, A Neurotrophic Factor in Nervous System Physiology
Current Medicinal Chemistry Protective Effect of Zinc on Mouse Renal Ischemia-reperfusion Injury by Anti-apoptosis and Antioxidation
Current Pharmaceutical Biotechnology Protective Effect of Notoginsenoside R1 on an APP/PS1 Mouse Model of Alzheimer's Disease by Up-Regulating Insulin Degrading Enzyme and Inhibiting Aβ Accumulation
CNS & Neurological Disorders - Drug Targets Role of Free Radicals in Sepsis: Antioxidant Therapy
Current Pharmaceutical Design White Matter Injury Mechanisms
Current Molecular Medicine Curcumin: Structure-Activity Relationship Towards its Role as a Versatile Multi-Targeted Therapeutics
Mini-Reviews in Organic Chemistry NAMPT in Regulated NAD Biosynthesis and its Pivotal Role in Human Metabolism
Current Medicinal Chemistry Experimental Developments and Review of Recent Patents for the Repair of Skeletal Muscles by Methods of Regenerative Medicine
Recent Patents on Regenerative Medicine Effect of Standardized Hydroalcoholic Extract of Saffron Stamen on High Blood Pressure and Baroreflex Sensitivity in Anesthetized Rats
Endocrine, Metabolic & Immune Disorders - Drug Targets Management of Hypertension in the Acute Phase of Stroke
Current Hypertension Reviews A Comprehensive Review on Chrysin: Emphasis on Molecular Targets, Pharmacological Actions and Bio-pharmaceutical Aspects
Current Drug Targets Global View on Rare Diseases: A Mini Review
Current Medicinal Chemistry Proteomic Validation of Protease Drug Targets: Pharmacoproteomics of Matrix Metalloproteinase Inhibitor Drugs Using Isotope-Coded Affinity Tag Labelling and Tandem Mass Spectrometry
Current Pharmaceutical Design